Anti-Human CD13 - DyLight® 594
| Code | Size | Price |
|---|
| LEI-C1667-50ug | 50 ug | £159.00 |
Quantity:
| LEI-C1667-100ug | 100 ug | £211.00 |
Quantity:
| LEI-C1667-200ug | 200 ug | £291.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG
Antibody Clonality: Monoclonal
Antibody Clone: 22A5
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
2-8°C
Storage:
This DyLight® 594 conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
The CD13 antigen is present on most cells of myeloid origin, including granulocytes and monocytes in normal peripheral blood. CD13 is not expressed on B-cells, T-cells, platelets or erythrocytes. Expression of this antigen is greater on monocytes than on granulocytes.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 594
Format:
This DyLight® 594 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 594 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Human CD13 (>98%)
Long Description:
Anti-Human CD13 can be used to study myeloid cell functions as well as to immunophenotype leukemias. CD13 is present on basophils from subjects with chronic myeloid leukemia (CML) and on granulocytes from subjects with systemic lupus erythematosus (SLE).
NCBI Gene:
290
Target:
CD13
References
1. Horton, A. M. et al. (1985) Cancer Res. 45:5663
Related Products
| Product Name | Product Code | Supplier | Anti-Human CD13 - DyLight® 755 | LEI-C1671 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human CD13 - PerCP | LEI-C1673 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||